SCHEMBL4295075

SCHEMBL4295075

CC(CCCOCn1cnc2c(=O)nc(N)[nH]c21)C(N)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
HBB P68871 2/20 0.48
MAPK1 P28482 1/20 0.48
PNP P00491 7/20 0.43
BLM P54132 2/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
EDNRA P25101 1/20 0.43
HTR2A P28223 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HPRT1 P00492 4/20 0.43
PDE3A Q14432 1/20 0.38
POLG P54098 1/20 0.37
GAA P10253 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16468669 0.83 PDE3A (0.51) KMT2AMEN1HBBMAPK1PNP
SCHEMBL4281488 0.83 PDE3A (0.51) KMT2AMEN1HBBMAPK1PNP
Valacyclovir SCHEMBL4295083 0.81 KMT2A (0.72) KMT2AMEN1HBBMAPK1PNP
Valacyclovir SCHEMBL34375 0.81 KMT2A (0.72) KMT2AMEN1HBBMAPK1PNP
Valacyclovir SCHEMBL29689659 0.80 HBB (0.72) KMT2AMEN1HBBMAPK1PNP
Valacyclovir SCHEMBL1888797 0.80 KMT2A (0.69) KMT2AMEN1HBBMAPK1PNP
Acyclovir SCHEMBL40723 0.78 PNP (0.67) KMT2AMEN1HBBMAPK1PNP
SCHEMBL15655101 0.78 MEN1 (0.45) KMT2AMEN1HBBMAPK1PNP
SCHEMBL4295065 0.78 MEN1 (0.45) KMT2AMEN1HBBMAPK1PNP
SCHEMBL23948433 0.77 KMT2A (0.53) KMT2AMEN1HBBMAPK1PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200046715-A1 Medicament for Treating Peripheral Neuropathies HSIAO LILY (TW) 2020-02-13 US claimed
US-10471064-B2 Medicament for treating peripheral neuropathies Hsiao, Lily (TW) 2019-11-12 US claimed
US-20180193348-A1 Medicament for Treating Peripheral Neuropathies HSIAO LILY (TW) 2018-07-12 US claimed
US-20170056408-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES YU HSIAO LILY (JP) 2017-03-02 US claimed
US-9549930-B2 Combined systemic and topical treatment of disordered and/or prodromal stage tissue QUADEX PHARMACEUTICALS, LLC (US) 2017-01-24 US claimed
US-9545408-B2 Combined systemic and topical treatment of disordered tissues QUADEX PHARMACEUTICALS, INC. (US) 2017-01-17 US claimed
US-9526729-B2 Medicament for treating peripheral neuropathies Yu, Hsiao Lily (JP) 2016-12-27 US claimed
US-20150238493-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES YU HSIAO LILY (JP) 2015-08-27 US claimed
US-20140213600-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES HSIAO LILY (TW) 2014-07-31 US claimed
US-20230218644-A1 COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS EWHA WOMANS UNIVERSITY (KR) 2023-07-13 US disclosed
US-20220169705-A1 TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE) 2022-06-02 US disclosed
US-11267871-B2 Topical application for an anti-HSV antibody Heiselberg ImmunoTherapeutics GmbH (DE) 2022-03-08 US disclosed
WO-2021209563-A1 COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS SOM INNOVATION BIOTECH, S.A. (ES) 2021-10-21 WO disclosed
EP-3160997-B1 TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE) 2020-10-28 EP disclosed
WO-2014160369-A1 COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES QUADEX PHARMACEUTICALS, LLC (US) 2014-10-02 WO disclosed
US-20140274939-A1 COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES QUADEX PHARMACEUTICALS, LLC (US) 2014-09-18 US disclosed
US-20140213600-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES HSIAO LILY (TW) 2014-07-31 US disclosed
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS PIVOT HOLDING LLC 2014-05-01 US disclosed
WO-2009129094-A2 COMPOSITIONS CONTAINING ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME MALLINCKRODT INC. (US) 2009-10-22 WO disclosed
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same MALLINCKRODT INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140274939-A1 COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES SAMHD1, DCTD, NT5E KMT2A 4660/4885MEN1 4618/4885HBB 1441/4885
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same EIF2AK2, MAVS, IRF3 KMT2A 3346/4885MEN1 3203/4885HBB 3885/4885
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS TPMT, BHMT2, PFAS KMT2A 645/4885MEN1 260/4885HBB 2021/4885
US-20230218644-A1 COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS ACE2, ACE, TMPRSS2 KMT2A 1324/4885MEN1 2508/4885HBB 4552/4885
US-20140213600-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES PMP22, DPM1, SUCLG1 KMT2A 1711/4885MEN1 632/4885HBB 2084/4885
US-10471064-B2 Medicament for treating peripheral neuropathies NGF, TSLP, BDNF KMT2A 920/4885MEN1 4356/4885HBB 4273/4885
US-20200046715-A1 Medicament for Treating Peripheral Neuropathies NGF, PMP22, BPGM KMT2A 1810/4885MEN1 3466/4885HBB 2477/4885
US-20180193348-A1 Medicament for Treating Peripheral Neuropathies NGF, TSLP, BDNF KMT2A 920/4885MEN1 4356/4885HBB 4273/4885
US-20170056408-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES PMP22, SNCA, PARL KMT2A 1917/4885MEN1 1309/4885HBB 1450/4885
US-20150238493-A1 MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES PMP22, SNCA, PARL KMT2A 1917/4885MEN1 1309/4885HBB 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.